Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jun Teishima

Showing results (151-160 of 240) with videos related to

Pageof 24
Sort By:
Japanese Journal of Clinical Oncology|February 27, 2020
Impact of radiological morphology of clinical T1 renal cell carcinoma on the prediction of upstaging to pathological T3Jun Teishima, Tetsutaro Hayashi, Hiroyuki Kitano, et al.
Molecular and Clinical Oncology|May 19, 2017
Body mass index as a classifier to predict biochemical recurrence after radical prostatectomy in patients with lower prostate-specific antigen levelsKeisuke Goto, Hirotaka Nagamatsu, Jun Teishima, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|June 11, 2020
Impact of the systemic immune-inflammation index for the prediction of prognosis and modification of the risk model in patients with metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitorsJun Teishima, Shogo Inoue, Tetsutaro Hayashi, et al.
Urologic Oncology|March 7, 2020
Microtubule-associated protein tau (MAPT) is a promising independent prognostic marker and tumor suppressive protein in clear cell renal cell carcinomaXiangrui Han, Yohei Sekino, Takashi Babasaki, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|May 16, 2017
Impact of neutrophil-to-lymphocyte ratio on effects of targeted therapy for metastatic renal cell carcinoma patients with extrapulmonary metastasisJun Teishima, Shinya Ohara, Kousuke Sadahide, et al.
Histopathology|October 22, 2011
Desmocollin 2 is a new immunohistochemical marker indicative of squamous differentiation in urothelial carcinomaTetsutaro Hayashi, Kazuhiro Sentani, Naohide Oue, et al.
European Urology|June 22, 2005
Urological retroperitoneoscopic surgery for patients with prior intra-abdominal surgeryKoji Mita, Masanobu Shigeta, Kazuaki Mutaguchi, et al.
Japanese Journal of Clinical Oncology|February 11, 2026
Risk stratification by pathological upstaging and tumor necrosis in clinical T1 clear-cell renal cell carcinoma: evidence from a multi-institutional cohort of 1081 patientsHideto Ueki, Takuto Hara, Taisuke Tobe, et al.
Journal of Bone and Mineral Metabolism|September 12, 2024
Temporal declines in bone mineral density and trabecular bone score during androgen deprivation therapyTakuto Hara, Hanako Nishimoto, Tomoaki Terakawa, et al.
Urologic Oncology|June 28, 2014
Identification of PRL1 as a novel diagnostic and therapeutic target for castration-resistant prostate cancer by the Escherichia coli ampicillin secretion trap (CAST) methodShunsuke Shinmei, Kazuhiro Sentani, Tetsutaro Hayashi, et al.
Pageof 24

Showing results (151-160 of 240) with videos related to

Sort By:
Pageof 24
Japanese Journal of Clinical Oncology|February 27, 2020
Impact of radiological morphology of clinical T1 renal cell carcinoma on the prediction of upstaging to pathological T3Jun Teishima, Tetsutaro Hayashi, Hiroyuki Kitano, et al.
Molecular and Clinical Oncology|May 19, 2017
Body mass index as a classifier to predict biochemical recurrence after radical prostatectomy in patients with lower prostate-specific antigen levelsKeisuke Goto, Hirotaka Nagamatsu, Jun Teishima, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|June 11, 2020
Impact of the systemic immune-inflammation index for the prediction of prognosis and modification of the risk model in patients with metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitorsJun Teishima, Shogo Inoue, Tetsutaro Hayashi, et al.
Urologic Oncology|March 7, 2020
Microtubule-associated protein tau (MAPT) is a promising independent prognostic marker and tumor suppressive protein in clear cell renal cell carcinomaXiangrui Han, Yohei Sekino, Takashi Babasaki, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|May 16, 2017
Impact of neutrophil-to-lymphocyte ratio on effects of targeted therapy for metastatic renal cell carcinoma patients with extrapulmonary metastasisJun Teishima, Shinya Ohara, Kousuke Sadahide, et al.
Histopathology|October 22, 2011
Desmocollin 2 is a new immunohistochemical marker indicative of squamous differentiation in urothelial carcinomaTetsutaro Hayashi, Kazuhiro Sentani, Naohide Oue, et al.
European Urology|June 22, 2005
Urological retroperitoneoscopic surgery for patients with prior intra-abdominal surgeryKoji Mita, Masanobu Shigeta, Kazuaki Mutaguchi, et al.
Japanese Journal of Clinical Oncology|February 11, 2026
Risk stratification by pathological upstaging and tumor necrosis in clinical T1 clear-cell renal cell carcinoma: evidence from a multi-institutional cohort of 1081 patientsHideto Ueki, Takuto Hara, Taisuke Tobe, et al.
Journal of Bone and Mineral Metabolism|September 12, 2024
Temporal declines in bone mineral density and trabecular bone score during androgen deprivation therapyTakuto Hara, Hanako Nishimoto, Tomoaki Terakawa, et al.
Urologic Oncology|June 28, 2014
Identification of PRL1 as a novel diagnostic and therapeutic target for castration-resistant prostate cancer by the Escherichia coli ampicillin secretion trap (CAST) methodShunsuke Shinmei, Kazuhiro Sentani, Tetsutaro Hayashi, et al.
Pageof 24